ANTI-miRNA-99b DAN miRNA-223 DALAM VAKSIN INFLUENZA SEBAGAI INOVASI TERAPI TUBERKULOSIS

FREDERICK ALEXANDER

Abstrak


Tuberculosis disebabkan oleh Mycobacterium Tuberculosis dapat ditularkan melalui percikan dahak (droplet) dari seorang penderita kepada individu lain yang rentan. Berdasarkan laporan World Health Organization (WHO) pada tahun 2015, hampir 9,6 juta kasus TB baru telah muncul dan angka kejadian kematian pada tahun 2014 berjumlah 1,5 juta. Terapi yang umum diberikan pada pasien TB saat ini melalui pemberian obat anti-TB per oral. Lamanya durasi pengobatan meningkatkan peluang ketidakpatuhan pasien selama pengobtan yang akhirnya akan mengakibatkan risiko Multi Drug Resistance (MDR-TB). Penyisipan Anti-miRNA-99b dan miRNA-223 dalam vaksin influenza sebagai inovasi terapi baru diharapkan dapat meningkatkan efikasi, efektifitas, dan kepraktisan pengobatan TB.

Kata Kunci


Tuberkulosis; anti-miRNA-99b; miRNA-223; Vaksin Influenza; Tuberculosis; anti-miRNA-99b; miRNA-223; Influenza Vaccine

Teks Lengkap:

PDF

Referensi


Centers for Disease Control and Prevention. 2016. Treatment for TB disease. US department of Health and Human Services. Available online at https://www.cdc.gov/tb/topic/treatment/tbdisease.htm [diakses online 14 Maret 2017].

Chen, Shun-Hsing, et.al. 2011. Integration Servqual model and performance control matrix to improve service quality for the hot spring industry. Journal Business.

Departemen Kesehatan Republik Indonesia. 2013. Peraturan Menteri Kesehatan Nomor 42 Tahun 2013 Tentang Penyelenggaraan Imunisasi. Departemen Kesehatan Republik Indonesia. Jakarta: Depkes RI.

Dorhoi A, Iannaccone M, Farinacci M, Fae KC, Schreiber J, et al. 2013. MicroRNA-223 controls susceptibility to Tuberculosis by regulating lung neutrophil recruitment. J Clin Invest 123(11): 4836-4848.

Ebbesen M., Jensen T.G., Andersen S., Pederesen S. 2008. Ethical Perspectives on RNA Interference Therapeutics. Int J Med Sci. 5(3): 159-168

Fu Y., Yi Z., Wu X., Li J., Xu F. 2011. Circulating microRNAs in patients with active pulmonary Tuberculosis. J Clin Microbiol 49(12): 4246- 4251.

Jordao, L. Dan Otilia V. Vieira. 2011. Tuberculosis: New Aspects of an Old Disease. International Journal of Cell Biology. Volume 2011.

Kanthikeel S.P. dan Nair M.P.N. 2015. Interaction of Drugs of Abuse and

microRNA with HIV: A Brief Review. Front. Mirobiol. 6(967). Doi:

3389/fmicb.2015.00967.

Kim D.H. dan Rossi J.J. 2008. RNAi Mechanism and Applications. Biotechniques. 44(5): 613-616

Kumar P., Ban, H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., Laouar A., et al. 2008. T Cell-Specific siRNA Delivery Supresses HIV-1 Infection in Humanized Mice. Cell. 134(4): 577-586.

Laurenzi, M., A. Ginsberg dan M. Spigelman. 2007. Challenges Associated with Current and Future TB Treatment. Infectious Disorders - Drug Targets 2007, 7, 105-119.

Li J, Arevalo M.T., dan Zeng M. 2013. Engineering Influenza Viral Vectors. Bioengineered. 4(1): 9–14

Li M, Ding X., He M., Cheung S. 2011. MicroRNA and cancer. APPS J.201Bovell L,Putcha B, Samuel T, Manne U. Clinical implications of microRNAs in cancer. Biotech Histochem. 88(7):388–96.

Ma F, Xu S, Liu X, Zhang Q, Xu X, et al. (2011) The microRNA miR- 29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 12(9): 861-869.

Mirbase.org. 2017. Stem-loop sequence hsa-mir-223. Available online at http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000300 [diakses online 19 Maret 2017].

National Cancer Institute. 2017. Polymorphonuclear Leukocyte. Available online at https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=633963 [diakses online 19 Maret 2017].

O’ Connel, R.M., Rao D. S., Chaudhuri A. A., dan Baltimore D. 2010.

Physiological and pathological roles for microRNAs in the Immune

system. Nat Rev Immunol 10(2): 111-122

Peyron P., J. Vaubourgeix, Y. Poquet, F. Levillain, C. Botanch, F. Bardou, M. Da'é, J.F. Emile, B. Marchou, P.J. Cardona, C. de Chastellier and F. Altare. 2008. Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. Tuberculosis persistence. PLoS Pathog. 4: e1000204.

Shen X., Sun W., Shi Y., Xing Z., Su X. 2015. Altered Viral Replication and Cell Responses by Inserting MicroRNA Recognition Element into PB1 in Pandemic Influenza A Virus (H1N1) 2009. Mediators of Inflammation. 1-15. doi: 10.1155/2015/976575.

Sigma-Aldrich. 2017. Tumor Necrosis Factor-α (TNF-α). Available online at http://www.sigmaaldrich.com/life-science/cell-biology/cell-biology-products.html?TablePage=14576697 [diakses online 19 Maret 2017].

Singh Y, Kaul V, Mehra A, Chatterjee S, Tousif S, et al. 2013. Mycobacterium Tuberculosis Controls MicroRNA-99b (miR-99b) Expression in Infected Murine Dendritic Celss to Modulate Host Immunity. Journal of Biological Chemistry. Volume 288. No.7.

Somantri, I. 2007. Keperawatan Medikal Bedah: Asuhan Keperawatan pada Pasien dengan Gangguan Sistem Pernapasan. Jakarta: Salemba Medika.

Tenoever B. 2010. Live Attenuated Influenza Virus Vaccines Comprising Microrna Response Elements. Google Patents.

World Health Organization (WHO) . 2010. Treatments of Tuberculosis Guideline fourth Edition. World Health Organization. Jenewa.

World Health Organization (WHO). 2014. Global Tuberculosis Report 2014. World Health Organization. Jenewa.

World Health Organization (WHO). 2015. Global Tuberculosis Report 2015. World Health Organization. Jenewa.

World Health Organization (WHO). 2016. Global Tuberculosis Report 2016. World Health Organization. Jenewa.

Wuchty S, Arjona D, Bozdag S, Bauer PO. 2012. Involvement of microRNA Families in Cancer. Nucleic Acids Res. 40(17):8219–26.

Yang, N. 2015. An Overview of Viral and NonViral Delivery System fot MicroRNA. Int J Pharm Ivestig. 5(4): 179-181.

Zaman, K. 2010. Tuberculosis: A Global Health Problem. J Health Popul Nutr. Vol. 2: 111-113.

Zhang Y., Wang Z., Gemeinhart R.A. 2013. Progress in MicroRNA Delivery. J Control Release. 172 (3): 962-974




DOI: https://doi.org/10.24198/jf.v15i2.12105

DOI (PDF): https://doi.org/10.24198/jf.v15i2.12105.g5756

Refbacks

  • Saat ini tidak ada refbacks.




Sitasi manajer:   

 

 

Jurnal ini diindeks dalam:

 

 

View My Stats 

ISSN: 1693-1424

e-ISSN: 2716-3075

 

Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Copyright © 2013 Jurnal Farmaka - All Right Reserved